Yatharth Hospital Targets Upwards Of 24% EBITDA Margin and ₹75-80 Lakh CapEx Per Bed

Market snapshot: Yatharth Hospital & Trauma Care Services Limited delivered strong strategic guidance alongside its robust Q1 FY27 results, maintaining its long-term expansion objectives. The company is on track to achieve an EBITDA margin upwards of 24% for FY27, backed by rapid breakeven timelines at newly added facilities. Additionally, a disciplined capital allocation plan has been established for its next phase of bed additions.

Data Snapshot

• Consolidated Revenue from Operations grew to ₹392.65 cr in Q1 FY27, representing a 51.5% YoY expansion.
• EBITDA rose to ₹91.7 cr in Q1 FY27, registering a 39% YoY growth.
• Profit After Tax (PAT) increased to ₹45.42 cr in Q1 FY27, up 8% YoY.
• Average Revenue Per Occupied Bed (ARPOB) reached ₹34,758, growing 7% YoY.

What's Changed

• Consolidated revenue increased to ₹392.65 cr in Q1 FY27 from ₹259.2 cr in Q1 FY26 (derived: +51.5% YoY).
• EBITDA rose to ₹91.7 cr in Q1 FY27 compared to ₹66 cr in Q1 FY26 (derived: +39% YoY).
• Consolidated EBITDA margin compressed to 23.3% in Q1 FY27 from 25.4% in Q1 FY26 due to staffing and ramp-up costs.
• Net profit grew to ₹45.42 cr in Q1 FY27 from ₹42.04 cr in Q1 FY26 (derived: +8% YoY).

Key Takeaways

• Yatharth is on track to achieve an EBITDA margin upwards of 24% for FY27, backed by strong volume scaling.
• The next 1,800 beds are planned at a CapEx of ₹75 lakh to ₹80 lakh per bed, while the upcoming Gurugram hospital will cost nearly ₹1 crore per bed.
• New hospital integrations are exceeding expectations; Faridabad Sector-20 reached EBITDA breakeven in a record nine months, and Agra registered a 20%+ EBITDA margin in its first full quarter of integration.
• The Board has approved a maiden interim dividend of 5% of the face value (₹0.50 per equity share) for the financial year 2026-27.

SAHI Perspective

Yatharth Hospital's Q1 FY27 performance demonstrates strong operational scaling, with a 51.5% YoY top-line expansion driven by inorganic additions. While the consolidated EBITDA margin compressed by 209 bps to 23.3% due to initial ramp-up costs of newer facilities, the adjusted EBITDA margin remained extremely robust at 28.1%. The company's disciplined capital expenditure model of ₹75 lakh to ₹80 lakh per bed for its next 1,800 beds reflects an asset-light and brownfield strategy that balances expansion with high return on capital. The higher CapEx of ₹1 crore per bed in Gurugram is justified by premium local real estate and advanced technology, positioning Yatharth to capture premium medical travel and high ARPOB patient mixes.

Market Implications

The guidance of surpassing 36% revenue growth and achieving upwards of 24% EBITDA margins in FY27 reinforces investor confidence in Yatharth's acquisition-driven expansion playbook. The quick breakeven cycle of new units significantly reduces the drag of new beds on overall return ratios. Continued volume growth and ARPOB expansion are expected to offset near-term margin dilution from ramp-up costs, driving mid-to-long term earnings acceleration.

Trading Signals

Market Bias: Bullish

Yatharth's strong Q1 FY27 performance with ₹392.65 cr in revenue, a record 51.5% YoY expansion, and a stable EBITDA margin guidance above 24% supports a positive outlook.

Overweight: Hospitals, Healthcare Services

Trigger Factors:

• Commencement of operations at the 250-bed Gurugram facility by Q1 FY28.
• Sustained occupancy improvement above the current 68% level across the network.
• Ramping up ARPOB to the ₹50,000 mark at new premium facilities.

Time Horizon: Medium-term (3–12 months)

Industry Context

The Indian healthcare sector is witnessing robust growth, projected to expand at a healthy CAGR of ~11% over FY23-FY27. Growth is being propelled by rising disposable incomes, higher health insurance penetration, and strong post-pandemic demand for premium tertiary care. In this landscape, hospital chains utilizing a 'hub-and-spoke' or regional cluster model in high-demand regions like Delhi-NCR are enjoying enhanced operating leverage. Yatharth’s rapid turnaround of distressed or underperforming acquired assets allows it to expand capacity at a lower cost than pure greenfield developers.

Key Risks to Watch

• Any future extension of government price controls on medical implants or essential pharmaceuticals could compress margins.
• Slower-than-expected volume ramp-ups at the upcoming Gurugram or newly added beds could extend the breakeven period.
• High concentration of bed capacity in the Delhi-NCR region makes Yatharth vulnerable to local competitive intensity.

Recent Developments

Yatharth Hospital announced the launch of its new ESOP Scheme 2026 covering 2,50,000 equity shares, aimed at attracting and retaining high-quality clinical and management talent. Additionally, the Board declared its maiden interim dividend of 5% of face value (₹0.50 per share) for FY27, totaling ₹4.82 crore.

Closing Insight

Yatharth Hospital's transition from a regional player to a highly efficient multi-specialty NCR champion is validated by its Q1 FY27 performance and ambitious 5,000-bed roadmap. By managing bed CapEx tightly at ₹75-80 lakh per bed and aggressively driving newly acquired facilities to breakeven, the company continues to demonstrate that aggressive scaling does not have to come at the cost of balance sheet health.

High Performance Trading with SAHI.